Lupin is currently trading at Rs. 943.55, up by 31.60 points or 3.47% from its previous closing of Rs. 911.95 on the BSE.
The scrip opened at Rs. 915.35 and has touched a high and low of Rs. 953.40 and Rs. 915.35 respectively. So far 159499 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 953.40 on 15-Jun-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 953.40 and Rs. 881.00 respectively. The current market cap of the company is Rs. 42768.86 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.
Lupin is planning to approach the US health regulator for re-inspection of its manufacturing plants in Goa, Pithampur (Madhya Pradesh) and Somerset (US) in the next few months. The company's Unit 2 manufacturing plant in Pithampur, along with its Goa site, is under the US Food and Drug Administration's (USFDA) warning letter since November 2017 for violation of current goods manufacturing practices. The US drug regulator, after inspecting the two sites, had expressed concerns over quality-control procedures that include handling of out-of-specification results and conducting hold-time studies.
On the other hand, the Somerset (New Jersey) plant is currently under the official action indicated (OAI) status, which means the USFDA may withhold approvals of pending applications or supplements from the facility.
Lupin is an innovation led transnational pharmaceutical company headquartered in Mumbai, India.
